Infections occurred worldwide in 2010 (5,6). The burden of dengue in Africa was recently estimated to be in the same range as that in Latin America (5,6). In Africa, locally acquired dengue cases have been reported from 22 countries during 1960–2010, and there is evidence of transmission in 34 countries (2). The burden of dengue in Africa was recently estimated to be in the same range as that in Latin America (5,6).

In 2013, a 71-year-old man came to the Tropical Medicine Clinic at Heidelberg University Hospital (Heidelberg, Germany) with suspected dengue fever 3 days after returning from West Africa to Germany. The patient had traveled for ≈6 weeks from mid-September through mid-October 2013 to Togo (Lomé, first 3 weeks), Benin (Ouidah, 1 week), back to Togo (Lomé, 1 week), and Burkina Faso (Ouagadougou, 3 days).

Tests results for DENV nonstructural protein 1 and IgM against DENV were positive. The result of a real-time reverse transcription PCR for DENV 1–4 was also positive. A serotype-specific real-time reverse transcription PCR identified DENV-3 (3,4).

To obtain the sequence of a 1,479-nt fragment of the complete gene of the envelope glycoprotein gene, we designed generic primers specific for all complete DENV-3 genomes available from GenBank (alignment was performed by using Geneious version 6.1; http://www.geneious.com), which were then sequentially adapted to sequences obtained (primers and protocol available upon request). Sequencing of the complete envelope glycoprotein gene of the virus isolated from the patient identified DENV-3 genotype III (GenBank accession no. KJ922394).

For phylogenetic comparison, we chose all DENV-3 sequences available from Africa and neighboring regions and a set of global sequences that represented different genotypes; DENV-1 was used as an outgroup. Sequences were aligned on the basis of translated nucleotide sequences, and a neighbor-joining tree with p-distance was inferred with 1,000 bootstrap replicates in MEGA version 5.2.1 (http://www.megasoftware.net/) for a 1,479-nt fragment spanning the complete gene of the envelope glycoprotein and a smaller fragment of 220 nt (Figure). We observed clustering of the virus sequence with those of strains from Côte d’Ivoire and Benin. Genetic identity was 99% with strains from Côte d’Ivoire (AB447989) (1,472/1,479 nt) and Benin (AB690858) (1,469/1,479nt).

Because of limited availability of only 4 complete envelope glycoprotein gene sequences from Africa, an additional phylogenetic analysis was performed with a smaller fragment of 220 nt to include more sequences of African origin. A total of 7 sequences, including additional sequences from Senegal and Cameroon, were available. Clustering of sequences of African origin was confirmed in this analysis; highest sequence identity of virus isolated from the patient was with viruses isolated in Côte d’Ivoire and Benin.

Nearly all sequence data for DENV-3 from Africa originate from returning travelers, such as reports of imported cases in 2006 from Cameroon to Spain (5), from Senegal to Spain in 2007 and to Italy in 2010 (5,6), from Côte d’Ivoire to France and Japan in 2008 (7,8), from Benin to Japan and France in 2010 (8,9), and from Eritrea to Finland in 2010 (5). Phylogenetic analysis of virus strains
Figure. Phylogenetic trees of A) a 1,479-nt fragment of the complete envelope glycoprotein gene and B) a 220-nt fragment of the partial envelope glycoprotein gene of dengue virus. Phylogeny was based on a neighbor-joining tree with p-distance and 1,000 bootstrap replicates. Bootstrap values >75 are indicated along the branches. The strain isolated in this study from a 71-year-old man who returned from West Africa to Germany is indicated in bold. Scale bars indicate percentage of nucleotide distance.
identified in these cases shows clustering with sequences of African origin, as observed for our patient (6–8). However, because only a small number of sequences of DENV-3 strains from Africa are available (and not all sequences refer to the same genomic region), a comparative phylogenetic analysis of strains from Africa is limited. A recent investigation of febrile patients from Gabon showed not only circulation of DENV-3, but simultaneous circulation of 3 DENV serotypes (DENV-1, DENV-2, and DENV-3) in West Africa (10).

Molecular data for travelers are useful in areas where DENV diagnosis and surveillance are not routinely performed. The case-patient reported here highlights sustained transmission of DENV-3 genotype III strains or closely related strains during recent years. Increasing numbers of reports on local outbreaks and available phylogenetic information support ongoing DENV-3 transmission in West Africa. If one assumes a maximum incubation time of 14 days, our case-patient was most probably exposed to DENV in Togo or Burkina Faso. These 2 countries have not been considered as areas to which DENV is endemic. Our findings indicate that further systematic evaluation of the risk and disease burden of dengue in Africa is urgently needed. Dengue fever should be considered in travelers returning from Africa with acute febrile illness.

Acknowledgments
We thank Ulrike Reber for excellent technical assistance and Victor M. Corman for assistance with phylogenetic analysis.

References
1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496:504–7. http://dx.doi.org/10.1038/nature12060
2. Amarasinghe A, Kuritsk JN, Letson GW, Margolis HS. Dengue virus infection in Africa. Emerg Infect Dis. 2011;17:1349–54.
3. Johnson BW, Russell BJ, Lanciotti RS. Serotype-specific detection of dengue viruses in a fourplex real-time reverse transcriptase PCR assay. J Clin Microbiol. 2005;43:4977–83. http://dx.doi.org/10.1128/JCM.43.10.4977-4983.2005
4. Drosten C, Gottig S, Schilling S, Asper M, Panning M, Schmitz H, et al. Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol. 2002;40:2323–30. http://dx.doi.org/10.1128/JCM.40.7.2323-2330.2002
5. Franco L, Di Caro A, Carletti F, Vapalahlal O, Renaudat C, Zeller H, et al. Recent expansion of dengue virus serotype 3 in West Africa. Euro Surveill. 2010;15 pii: 19490.
6. Nissi C, Carletti F, Castilletti C, Bordi L, Meschi S, Selleri M, et al. A case of dengue type 3 virus infection imported from Africa to Italy, October 2009. Euro Surveill. 2010;15 pii: 19487.
7. Ninove L, Parola P, Baronti C, De Lamballerie X, Gautret P, Doudier B, et al. Dengue virus type 3 infection in traveler returning from West Africa. Emerg Infect Dis. 2009;15:1871–2. http://dx.doi.org/10.3201/eid1511.081736
8. Moi ML, Ujiie M, Takasaki T, Kurane I. Dengue virus infection in travellers returning from Benin to France, July–August, 2010. Euro Surveill. 2010;15:19674.
9. Moi ML, Takasaki T, Kotaka A, Tajima S, Lim CK, Sakamoto M, et al. Importation of dengue virus type 3 to Japan from Tanzania and Côte d’Ivoire. Emerg Infect Dis. 2010;16:1770–2. http://dx.doi.org/10.3201/eid1611.101061
10. Caron M, Grard G, Paupy C, Monbo IM, Bikie Bi Nso B, Kassa Kassa FR, et al. First evidence of simultaneous circulation of three different dengue virus serotypes in Africa. PLoS ONE. 2013;8:e78030. http://dx.doi.org/10.1371/journal.pone.0078030

Address for correspondence: Isabella Eckerle, Institute of Virology, University of Bonn Medical Centre, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany; email: eckerle@virology-bonn.de

Community-Acquired Invasive GAS Disease among Native Americans, Arizona, USA, Winter 2013

Aaron M. Harris,1 Del Yazzie,1 Ramona Antone-Nez, Gayle Diné-Chacon, J.B. Kinlacheeny, David Foley, Seema Yasmin, Laura Adams, Eugene Livar, Andrew Terranella, Linda Yeager, Ken Komatsu, Chris Van Beneden, and Gayle Langley

Author affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (A.M. Harris, S. Yasmin, L. Adams, C. Van Beneden, G. Langley); Navajo Division of Health, Window Rock, Arizona, USA (D. Yazzie, R. Antone-Nez, G. Diné-Chacon, J.B. Kinlacheeny, D. Foley); Arizona Department of Health Services, Phoenix, Arizona (E. Livar, K. Komatsu); and Indian Health Service, Navajo Area, Arizona (A. Terranella, L. Yeager)

DOI: http://dx.doi.org/10.3201/eid2101.141148

To the Editor: Group A streptococci (GAS) can cause severe invasive diseases, such as necrotizing fasciitis, streptococcal toxic shock syndrome, and sepsis. In 2012, 11,000 cases of invasive GAS (iGAS) disease and 1,100 associated deaths occurred in the United States (1,2). The risk for iGAS infection is 10 times higher among Native Americans than among the general population (3). Other predisposing factors for iGAS infection include skin wounds and underlying diseases, such as diabetes (1,3,4). Household risk factors include exposure to children with pharyngitis and crowding (4). Most iGAS infections occur sporadically within the community. Postpartum and postsurgical clusters arising from a common nosocomial source occur but are rare (5).

During the winter of 2012–13, a 3-fold increase in necrotizing fasciitis was observed at an Arizona hospital

1These authors contributed equally to this article.